Calamos Advisors LLC Sells 25,473 Shares of CryoPort, Inc. $CYRX

Calamos Advisors LLC decreased its holdings in CryoPort, Inc. (NASDAQ:CYRX) by 42.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,267 shares of the company’s stock after selling 25,473 shares during the period. Calamos Advisors LLC’s holdings in CryoPort were worth $596,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CYRX. State of Wyoming bought a new position in shares of CryoPort in the third quarter worth $81,000. Counterpoint Mutual Funds LLC purchased a new position in CryoPort during the 3rd quarter valued at about $324,000. State of Alaska Department of Revenue purchased a new position in CryoPort during the 3rd quarter valued at about $40,000. Engineers Gate Manager LP purchased a new position in CryoPort during the 2nd quarter valued at about $518,000. Finally, Squarepoint Ops LLC grew its holdings in CryoPort by 685.1% during the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after buying an additional 321,497 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Roth Capital reiterated a “buy” rating and set a $21.00 price target on shares of CryoPort in a research report on Friday, August 7th. Guggenheim raised their price objective on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. KeyCorp boosted their price objective on shares of CryoPort from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday. Robert W. Baird set a $26.00 price objective on shares of CryoPort in a research note on Tuesday, October 13th. Finally, Piper Sandler raised shares of CryoPort to a “buy” rating in a report on Tuesday, October 13th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.69.

CryoPort Stock Performance

Shares of CYRX stock opened at $20.47 on Tuesday. CryoPort, Inc. has a 52-week low of $7.61 and a 52-week high of $20.57. The company has a market capitalization of $1.04 billion, a PE ratio of -21.10 and a beta of 1.89. The business’s fifty day moving average is $17.07 and its 200 day moving average is $13.51.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. On average, sell-side analysts forecast that CryoPort, Inc. will post -0.83 EPS for the current fiscal year.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.